Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effectiveness and Safety of Tezepelumab in Severe Asthma (US Post-Authorization Study)
2026-000081-25Phase 4
- Sponsor
- AstraZeneca
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tezepelumab in severe asthma, sponsored by AstraZeneca. Primary endpoint: Annualized asthma exacerbation rate (AAER).
02
Drugs
03
Conditions
severe asthma
Beyond the preview
Go deeper on 2026-000081-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-000081-25.